

# Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN- $\alpha$ Failure and in Late CML-CP, Comparison with Historical Controls

Hagop Kantarjian,<sup>1</sup> Susan O'Brien,<sup>1</sup>  
 Jorge Cortes,<sup>1</sup> Francis Giles,<sup>1</sup> Jianqin Shan,<sup>1</sup>  
 Mary Beth Rios,<sup>1</sup> Stefan Faderl,<sup>1</sup>  
 Srđan Verstovsek,<sup>1</sup> Guillermo Garcia-Manero,<sup>1</sup>  
 William Wierda,<sup>1</sup> Steven Kornblau,<sup>1</sup>  
 Alessandra Ferrajoli,<sup>1</sup> Michael Keating,<sup>1</sup> and  
 Moshe Talpaz<sup>2</sup>

Departments of <sup>1</sup>Leukemia and <sup>2</sup>Bioimmunotherapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas

## ABSTRACT

**Purpose:** The purpose of this research was to compare the survival of patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) post-IFN- $\alpha$  failure treated with imatinib to historical experiences with standards of care or other therapies.

**Experimental Design:** The outcome of 261 patients with Ph-positive chronic phase CML post-IFN failure treated with imatinib was compared with 204 historical control patients treated for a similar disease status with existing therapies. A subset of 147 patients in late chronic phase CML and 100% Ph-positive status treated with imatinib was compared with 95 patients in a similar disease status treated with IFN. Multivariate analyses were conducted to assess the independent prognostic effect of therapy (imatinib *versus* other) on survival.

**Results:** In the first analysis involving 261 patients on imatinib plus 204 historical patients, the complete cytogenetic response rates were 62% and 19%, respectively ( $P < 0.001$ ). A multivariate analysis identified pretreatment peripheral blasts and thrombocytosis to be independent poor prognostic factors for survival. Imatinib therapy (*versus* others) was a significant independent favorable prognostic factor for survival (hazard ratio, 0.17;  $P < 0.0001$ ). In the second analysis involving the subset of 147 patients receiving imatinib plus 95 historical patients treated with IFN regimens, the complete cytogenetic response rates were 41% and

7%, respectively ( $P < 0.001$ ). A multivariate analysis selected pretreatment anemia and peripheral blasts to be significant independent poor prognostic factors for survival. Imatinib therapy (*versus* IFN) was an independent favorable prognostic factor for survival (hazard ratio, 0.20;  $P < 0.0001$ ). Three-month and 6-month landmark analyses showed that patients in all cytogenetic response categories (major, minor, and none) after imatinib therapy had survival outcomes better than the historical control population. Within each cytogenetic response category, survival was also better with imatinib than with other therapies.

**Conclusions:** This analysis provides evidence for a survival advantage with imatinib *versus* other therapies in chronic-phase CML post-IFN failure, and for a survival advantage with imatinib *versus* IFN in late chronic-phase CML.

## INTRODUCTION

Imatinib mesylate (Gleevec, STI571) is a selective Bcr-Abl tyrosine kinase inhibitor with significant activity in the treatment of Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) in chronic, accelerated, and blastic phases (1–12). In patients with chronic-phase CML post-IFN  $\alpha$  failure, imatinib induced complete cytogenetic response in 48% and major cytogenetic response (Ph  $< 35\%$ ) in 65% of patients. The estimated 2-year transformation rate was 13%, and the estimated 2-year survival rate was 92% (5). In an international randomized study of IFN plus 1- $\beta$ -D-arabinofuranosylcytosine (ara-C) *versus* STI571 (IRIS trial), in patients with previously untreated CML in early chronic-phase, imatinib was associated with significantly better 18-month rates of complete cytogenetic response (76% *versus* 14%;  $P < 0.001$ ), progression-free survival (91% *versus* 73%;  $P < 0.001$ ), and transformation (3% *versus* 9%;  $P < 0.001$ ). Because of the response and toxicity profiles, 89% of patients on IFN plus ara-C have already either crossed over to imatinib by design (58%) or were taken off study to be treated with commercially available imatinib (31%) after a median duration of 8 months of therapy (11). The 18-month estimated survival rates with imatinib *versus* IFN plus ara-C were 98% *versus* 95% ( $P = 0.16$ ). Thus, perhaps partly because of the high early crossover rate, a survival benefit with imatinib *versus* IFN plus ara-C may not be observed in the IRIS study. Other randomized studies of imatinib *versus* IFN-based therapy are unlikely to be conducted.

An alternative method to demonstrate a survival benefit with imatinib is a rigorous comparison of the maturing survival data with imatinib to historical control patients treated in the past with the standard of care. Recent studies suggested that well-defined observational studies yield similar results to com-


Received 7/14/03; revised 9/11/03; accepted 9/12/03.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Requests for reprints:** Hagop Kantarjian, M.D. Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030. Phone: (713) 792-7305; Fax: (713) 794-4297; E-mail: hkantarj@mdanderson.org.

**Table 1** Characteristics of the study group of 261 patients treated with imatinib and of the historical control group of 204 patients treated with nonimatinib therapies for chronic-phase chronic myelogenous leukemia post-IFN failure

| Characteristic                                   | Category     | Percentage |       | P                                |
|--------------------------------------------------|--------------|------------|-------|----------------------------------|
|                                                  |              | Imatinib   | Other |                                  |
| Age (years)                                      | ≥60          | 34         | 19    | 0.0002                           |
| Splenomegaly                                     | Present      | 10         | 23    | 0.0009                           |
| Hemoglobin (g/dl)                                | <12          | 38         | 54    | 0.0006                           |
| WBC ( $\times 10^9/l$ )                          | >50          | 9          | 25    | <0.0001                          |
| Platelets ( $\times 10^9/l$ )                    | >450         | 22         | 25    | 0.58                             |
| % marrow blasts                                  | ≥5           | 10         | 9     | 0.92                             |
| Peripheral blasts                                | Present      | 17         | 21    | 0.34                             |
| % marrow basophils                               | ≥4           | 20         | 14    | 0.11                             |
| % peripheral basophils                           | ≥7           | 11         | 11    | 0.94                             |
| Cytogenetic clonal evolution                     | Yes          | 9          | 14    | 0.18                             |
| Prognostic group (Sokal) (20)                    | Low          | 50         | 48    | 0.02                             |
|                                                  | Intermediate | 41         | 31    |                                  |
|                                                  | High         | 9          | 21    |                                  |
| Duration of chronic phase (months)               | <12          | 11         | 19    | 0.005                            |
|                                                  | 12–35        | 42         | 48    |                                  |
|                                                  | ≥36          | 47         | 34    |                                  |
| % Philadelphia-positive pretreatment IFN failure | <90          | 23         | 12    | 0.01                             |
|                                                  | Hematologic  | 14         | 33    | <0.0001                          |
|                                                  | Cytogenetic  | 48         | 35    | (0.17 for Intolerance vs. other) |
|                                                  | Intolerance  | 38         | 31    |                                  |



**Fig. 1** Survival of the 261 patients treated with imatinib and the 204 patients in the historical control group post-IFN failure by treatment.

parative randomized trials, provided they satisfy certain criteria (e.g., appropriate selection of controls, inability of the investigator or patient to choose therapy, and ethical and moral considerations disallowing such randomized designs; Refs. 13, 14).

In this analysis, we have compared the outcome of patients in chronic-phase CML post-IFN failure treated with imatinib to two other historical control groups (15–17). The first group is historical patients with CML post-IFN failure receiving nonimatinib therapies (when imatinib was not available). The second group is historical patients in late chronic-phase CML (diagnosis >12 months) treated with IFN therapy (imatinib also not available then). The latter group would provide a comparison of imatinib *versus* IFN (an accepted standard of care) in late chronic-phase CML. These patients had received IFN alone or in combinations on one of several protocols available throughout the time period at our institution.

## MATERIALS AND METHODS

**Study Group.** Two hundred sixty-one patients with Ph-positive CML in chronic-phase post-IFN failure treated with imatinib on the Food and Drug Administration pivotal trial (Novartis 110) and the Expanded Access Trial (Novartis 113) were analyzed (5, 6). Within this group of 261 patients, 147 patients had 100% Ph-positive disease and were compared with the second historical control group discussed below. Eligibility criteria, treatment design, dose modifications, management of side effects and monitoring, and follow-up have been detailed previously (5, 6).

**Historical Control Groups.** Two historical control groups were selected for analysis. The first historical study group included 204 patients with early chronic-phase CML treated with IFN-based regimens on our institutional protocols from 1982 until 1992 and, whose disease ultimately failed on IFN therapy (15–17). Details of these IFN programs and patient outcomes have been reported previously. The purpose of the historical group selection was to allow comparison of results with imatinib to results with nonimatinib therapies received by these patients who had CML post-IFN failure.

The second historical study group included 95 patients in

**Table 2** Response to therapy

| Response             | No. (%)               |                    |
|----------------------|-----------------------|--------------------|
|                      | Imatinib<br>(n = 261) | Other<br>(n = 204) |
| CHR <sup>a</sup>     | 254 (97)              | 108 (53)           |
| Cytogenetic response | 208 (80)              | 60 (29)            |
| Complete             | 162 (62)              | 39 (19)            |
| Partial              | 29                    | 10                 |
| Minor                | 17                    | 11                 |

<sup>a</sup> CHR, complete hematological response.

late chronic-phase CML (diagnosis  $\geq 12$  months) who received IFN regimens on institutional protocols from 1982 until 1997. These patients had received non-IFN therapies (*e.g.*, hydroxyurea, busulfan, or chemotherapy combinations) before IFN. The purpose of the second historical group selection was to compare results with imatinib to results with IFN, an accepted standard of care, in late chronic-phase CML.

**Response Criteria and Statistical Considerations.** Response criteria have been described previously (5, 6, 15–17). A complete hematological response was defined as a WBC count of  $<10 \times 10^9/\text{liter}$ ; a platelet count of  $<450 \times 10^9/\text{liter}$ ; no immature cells (blasts, promyelocytes, or myelocytes) in the peripheral blood; marrow blasts  $\leq 5\%$ ; and disappearance of all signs and symptoms related to leukemia (including palpable splenomegaly); the response lasting for at least 4 weeks. Response was additionally categorized by the best cytogenetic response: complete if no Ph-positive cells were present, partial if the proportion of Ph-positive cells was between 1% and 34%, and minor if the proportion of Ph-positive cells declined to between 35% and 90%. Major cytogenetic response was defined as the sum of complete plus partial cytogenetic responses (*i.e.*, all of the patients in whom Ph-positive cell proportions were  $<35\%$ ). The evaluation of cytogenetic response was judged by standard cytogenetic analysis of metaphase spreads. Time to disease progression was calculated from the time the treatment began until the first reported appearance of accelerated- or blastic-phase disease, discontinuation of therapy because of unsatisfactory response, or death. Survival was calculated from the time the treatment began until death from any cause or last follow-up.

Univariate and multivariate analyses were performed to identify potential prognostic factors and their association with survival (18). Significant prognostic factors by univariate analysis ( $P < 0.05$ ) were then included as terms in a multivariate regression model for survival. Factors retaining significance in the multivariate model were interpreted as being independently predictive of survival.

## RESULTS

**Study Groups and Outcome in Chronic-Phase CML Post-IFN Failure.** The pretreatment characteristics of the 261 patients treated with imatinib for chronic-phase CML post-IFN failure are shown in Table 1 and compared with the historical control group of patients receiving nonimatinib therapies post-IFN failure. Patients treated with imatinib were significantly older ( $P < 0.01$ ), had longer duration of chronic-phase disease ( $P = 0.01$ ), and included more patients with some extent of Ph suppression ( $P = 0.01$ ) and with cytogenetic resistance ( $P < 0.0001$ ). The historical group of patients treated with nonimatinib regimens had significantly higher incidences of splenomegaly ( $P < 0.01$ ), anemia ( $P < 0.01$ ), and leukocytosis ( $P < 0.0001$ ). Risk group distributions by the Hasford model (19) were similar (data not shown), but more patients in the historical group had high-risk disease by the Sokal model (20). Twenty-eight (14%) patients in the historical control group eventually received imatinib therapy after a median time of 129 months (range, 96–190 months). This added sequential therapy should, thus, have no effect on the comparison of early parts of the




Fig. 2 Survival of patients in chronic-phase chronic myelogenous leukemia post-IFN failure treated with imatinib or other regimens.

survival curves (3–4 year survivals). The median follow-up times were 34 months with imatinib and 109 months with other therapies.

At this time of follow-up, only 4 of 261 patients (2%) treated with imatinib underwent allogeneic stem cell transplant (SCT), 3 in chronic phase, 1 in second chronic phase: 2 of the 4 patients (both treated in chronic phase) are alive without disease 19+ and 28+ months from SCT.

Initial therapy in the 204 patients in the historical control after IFN failure included: allogeneic (SCT), 37; homoharringtonine-based therapy, 27; hydroxyurea and/or busulfan, 86; ara-C-based regimens, 24; and others (idarubicin, deoxycoformycin, thiotepea, and so forth), 30. The incidence of complete cytogenetic response with each approach was: allogeneic SCT, 28 of 37 (76%); homoharringtonine, 5 of 27 (19%); hydroxyurea and/or busulfan, 1 of 86 (1%); and ara-C regimens and others, 5 of 54 (9%). Survival by therapy is shown in Fig. 1. Among the 37 patients who underwent allogeneic SCT, 16 were alive and disease-free with a median follow-up of 127 months; the estimated 10-year survival rate was 42%. Sixty additional patients (of the 204; 29%) underwent allogeneic SCT after one or several of these treatments: 30 in chronic phase, 8 in accelerated phase, 12 in second chronic phase, and 10 in blastic phase. Ten (17%) of them are still alive without disease with a median follow-up time from SCT of 109+ months (range, 64–199+ months).

Response to imatinib and other therapies is shown in Table 2. The incidence of complete cytogenetic response was 62% with imatinib and 19% with other therapies ( $P < 0.001$ ), the latter mostly accounted for by the allogeneic SCT results. Survival of patients with imatinib *versus* other therapies is shown in Fig. 2. A univariate analysis of pretreatment factors associated with a survival benefit in the total group of 465 patients showed several characteristics to be prognostically important (Table 3). A multivariate analysis, excluding therapy (imatinib *versus* other), selected the following to be independent poor prognostic factors: peripheral blasts ( $P = 0.004$ ) and platelet counts ( $P = 0.02$ ). The addition of therapy (imatinib *versus* other), after accounting for important independent pretreatment factors, se-

Table 3 Associations of patient and disease characteristics with survival

| Parameter                          | Category         | No. | 2-yr % survival | 4-yr % survival | P (log rank) |
|------------------------------------|------------------|-----|-----------------|-----------------|--------------|
| Age (years)                        | <60              | 337 | 82              | 61              | 0.60         |
|                                    | ≥60              | 128 | 85              | 61              |              |
| Splenomegaly                       | No               | 337 | 89              | 70              | 0.0001       |
|                                    | Yes              | 57  | 63              | 49              |              |
| Hemoglobin (g/dl)                  | <12              | 207 | 78              | 56              | 0.06         |
|                                    | ≥12              | 251 | 87              | 65              |              |
| WBC ( $\times 10^9/l$ )            | ≤50              | 385 | 84              | 64              | 0.003        |
|                                    | >50              | 73  | 79              | 48              |              |
| Platelets ( $\times 10^9/l$ )      | ≤450             | 349 | 86              | 66              | <0.0001      |
|                                    | >450             | 107 | 75              | 42              |              |
| % peripheral basophils             | <7               | 402 | 85              | 64              | 0.0003       |
|                                    | ≥7               | 50  | 67              | 31              |              |
| Peripheral blasts                  | No               | 366 | 87              | 65              | <0.0001      |
|                                    | Yes              | 86  | 66              | 43              |              |
| % marrow basophils                 | <4               | 334 | 86              | 67              | 0.003        |
|                                    | ≥4               | 73  | 80              | 50              |              |
| % marrow blasts                    | <5               | 370 | 87              | 68              | <0.0001      |
|                                    | ≥5               | 38  | 62              | 26              |              |
| Cytogenetic clonal evolution       | No               | 364 | 87              | 66              | 0.05         |
|                                    | Yes              | 45  | 66              | 55              |              |
| Sokal risk (20)                    | Low              | 139 | 82              | 60              | 0.01         |
|                                    | Intermediate     | 100 | 83              | 58              |              |
|                                    | High             | 46  | 67              | 41              |              |
| Duration of chronic phase (months) | <12              | 66  | 82              | 57              | 0.20         |
|                                    | 12–35            | 207 | 85              | 64              |              |
|                                    | ≥36              | 192 | 81              | 58              |              |
| IFN failure                        | Hematologic      | 104 | 77              | 44              | 0.003        |
|                                    | Cytogenetic      | 198 | 86              | 68              |              |
|                                    | Intolerance      | 163 | 83              | 65              |              |
| % Philadelphia + pretreatment      | <90              | 77  | 94              | 84              | 0.005        |
|                                    | ≥90              | 329 | 83              | 60              |              |
| Study group                        | Study group      | 261 | 93              | –               | <0.0001      |
|                                    | Historical group | 204 | 71              | 44              |              |

lected imatinib to be still associated with a significant survival benefit (hazard ratio, 0.17;  $P < 0.0001$ ).

A repeat analysis, excluding the 37 patients who underwent allogeneic SCT, identified the same two independent prognostic factors, and showed the addition of therapy (imatinib *versus* other) to remain independently associated with survival benefit (hazard ratio, 0.2;  $P < 0.0001$ ).

**Study Groups and Outcome in Late Chronic-Phase CML.** We next investigated the outcome of patients with only late chronic-phase CML treated with imatinib post-IFN failure, and compared them with a group of historical controls treated with IFN regimens for late chronic-phase CML. These patients were IFN-naïve, and, therefore, different from the imatinib study group in this one aspect. However, our previous experience indicated that the outcome in late chronic-phase CML was not different by prior IFN exposure (21, 22). Thus, this second analysis allowed a comparison of imatinib results with a second set of historical controls receiving IFN in late chronic-phase CML. To harmonize the pretreatment characteristics of the two study groups, we analyzed only the subset of 147 patients on imatinib who had only late chronic-phase CML and who had 100% Ph-positive disease at the start of therapy. The median follow-up times were 33 months for the imatinib study group and 93 months for the IFN-treated historical control group. Twenty of the 95 patients (21%) in the historical group underwent allogeneic SCT: 11 in chronic phase, 6 in accelerated

phase/second chronic phase, and 3 in blastic phase. Five of the 20 patients are still alive without disease for a median follow-up time from SCT of 61+ months (range, 59+ to 87+ months).

Patients on imatinib were significantly older ( $P < 0.01$ ), but those receiving IFN therapy had significantly more frequent splenomegaly ( $P = 0.04$ ), leukocytosis ( $P < 0.01$ ), and peripheral blasts ( $P = 0.04$ ).

The characteristics of the two study groups are compared in Table 4. Complete cytogenetic response was significantly higher with imatinib *versus* IFN (41% *versus* 7%;  $P < 0.001$ ; Table 5). Survival of the two study groups is compared in Fig. 3. A univariate analysis of the total group of patients identified several characteristics as significant adverse prognostic factors (Table 6). A multivariate analysis of pretreatment factors (excluding therapy, imatinib *versus* IFN) selected anemia ( $P = 0.005$ ) and peripheral blasts ( $P = 0.003$ ) to be independent adverse prognostic factors. Adding therapy (imatinib *versus* IFN) after accounting for the independent significant pretreatment prognostic factors identified imatinib therapy to be associated with a significant survival advantage (hazard ratio, 0.2;  $P < 0.001$ ).

**Outcome of Patients Treated with Imatinib for Chronic-Phase CML Post-IFN Failure by Their 3-Month and 6-Month Cytogenetic Response; Comparison to Historical Controls.** Early response to imatinib has been shown to predict for long-term prognosis (5–8). Therefore, we analyzed

**Table 4** Characteristics of the study group of 147 patients treated with imatinib for late chronic-phase chronic myelogenous leukemia and starting with 100% Philadelphia-positive cells, and of the historical control group of 95 patients treated with IFN for late chronic-phase chronic myelogenous leukemia

| Characteristic no. treated         | Category     | Percentage |           | P       |
|------------------------------------|--------------|------------|-----------|---------|
|                                    |              | Imatinib   | IFN-based |         |
| Age (years)                        | ≥60          | 39         | 9         | <0.0001 |
| Splenomegaly                       | Present      | 14         | 25        | 0.04    |
| Hemoglobin (g/dl)                  | <12          | 43         | 37        | 0.42    |
| WBC ( $\times 10^9/l$ )            | >50          | 14         | 31        | 0.004   |
| Platelets ( $\times 10^9/l$ )      | >450         | 29         | 37        | 0.23    |
| % marrow blasts                    | ≥5           | 14         | 8         | 0.15    |
| Peripheral blasts                  | Present      | 27         | 40        | 0.04    |
| % marrow basophils                 | ≥4           | 24         | 15        | 0.12    |
| % peripheral basophils             | ≥7           | 15         | 17        | 0.83    |
| Cytogenetic clonal evolution       | Yes          | 13         | 17        | 0.51    |
| Prognostic group (20)              | Low          | 45         | 54        |         |
|                                    | Intermediate | 48         | 38        | 0.60    |
|                                    | High         | 7          | 8         |         |
| Duration of chronic phase (months) | 12–35        | 48         | 57        | 0.20    |
|                                    | ≥35          | 52         | 43        |         |
| IFN failure                        | Hematologic  | 19         | –         |         |
|                                    | Cytogenetic  | 51         | –         |         |
|                                    | Intolerance  | 30         | –         |         |

**Table 5** Response to therapy

| Response             | No. (percentage)      |                       |
|----------------------|-----------------------|-----------------------|
|                      | Imatinib<br>(n = 147) | IFN-based<br>(n = 95) |
| CHR <sup>a</sup>     | 140 (95)              | 55 (58)               |
| Cytogenetic response | 101 (69)              | 23 (24)               |
| Complete             | 61 (41)               | 7 (7)                 |
| Partial              | 26                    | 4                     |
| Minor                | 14                    | 12                    |


<sup>a</sup> CHR, complete hematological response.

the outcome of the study group of patients treated with imatinib for chronic-phase CML post-IFN failure by their 3-month cytogenetic response (major, minor, and others). Using a landmark analysis at 3 months (only patients alive at 3 months in the study and historical groups), a comparison of imatinib-treated patients to the historical control group of patients treated with nonimatinib therapies post-IFN failure demonstrated that patients receiving imatinib had a superior survival to patients treated with nonimatinib therapies regardless of their early response to imatinib (Fig. 4A). The estimated 3-year survival rates with imatinib from start of therapy were 98% with major cytogenetic response, 92% with minor cytogenetic response, and 84% with no cytogenetic response, compared with 60% in the historical group ( $P < 0.0001$ ). A similar landmark analysis at 6 months showed similar data. With imatinib, the estimated 3-year survival rates were 97% with major cytogenetic response, 100% with minor cytogenetic response, and 85% without a cytogenetic response, compared with 66% for the historical control group ( $P < 0.0001$ ). We then compared, by landmark analysis at 3 and 6 months, the outcome with imatinib *versus* other therapies within each cytogenetic response category achieved with each modality at 3 months and 6 months. As shown in Table 7,

survival with imatinib was superior to that with other therapies, even when similar cytogenetic responses were obtained.

## DISCUSSION

In cancer research designs, randomized controlled trials provide evidence of the highest grade, whereas observational trials are considered to be less valid because they may overestimate the treatment effects (23–26). Recent studies indicated that well-designed observational studies yield similar results to comparative randomized trials (13, 14), this perhaps being due to statistical methodologic improvements, including choice of data sets and better statistical methods. These studies have been criticized, however, and are not broadly accepted. Nevertheless, observational studies (with comparison to historical control results) may provide valuable data, particularly in instances when



**Fig. 3** Survival of patients in late chronic-phase chronic myelogenous leukemia and 100% Philadelphia-positive disease treated with imatinib or IFN therapy.

Table 6 Association of patient and disease characteristics with survival

| Parameter                     | Category         | No. | % 2-yr survival | % 4-yr survival | P (log rank) |
|-------------------------------|------------------|-----|-----------------|-----------------|--------------|
| Age (years)                   | <60              | 176 | 86              | 65              | 0.44         |
|                               | ≥60              | 66  | 87              | 47              |              |
| Splenomegaly                  | No               | 195 | 91              | 68              | 0.06         |
|                               | Yes              | 43  | 67              | 51              |              |
| Hemoglobin (g/dl)             | <12              | 98  | 90              | 70              | 0.01         |
|                               | ≥12              | 143 | 81              | 58              |              |
| WBC ( $\times 10^9/l$ )       | ≤50              | 191 | 87              | 67              | 0.03         |
|                               | >50              | 50  | 84              | 59              |              |
| Platelets ( $\times 10^9/l$ ) | ≤450             | 164 | 88              | 73              | 0.01         |
|                               | >450             | 77  | 83              | 50              |              |
| % peripheral basophils        | <7               | 203 | 88              | 69              | 0.03         |
|                               | ≥7               | 38  | 75              | 46              |              |
| Peripheral blasts             | No               | 162 | 92              | 70              | <0.01        |
|                               | Yes              | 75  | 75              | 53              |              |
| % marrow basophils            | <4               | 189 | 87              | 69              | <0.01        |
|                               | ≥4               | 50  | 81              | 47              |              |
| % marrow blasts               | <5               | 211 | 90              | 68              | <0.01        |
|                               | ≥5               | 28  | 59              | 47              |              |
| Cytogenetic clonal evolution  | No               | 207 | 87              | 65              | 0.70         |
|                               | Yes              | 35  | 82              | 62              |              |
| Sokal risk (20)               | Low              | 47  | 89              | 74              | 0.76         |
|                               | Intermediate     | 43  | 93              | 88              |              |
|                               | High             | 7   | 69              | 34              |              |
| Study group                   | Study group      | 147 | 91              | —               | <0.01        |
|                               | IFN (historical) | 95  | 78              | 55.3            |              |




Fig. 4 Comparison of the outcome of patients in chronic-phase chronic myelogenous leukemia post-IFN failure treated with imatinib by their 3-month (A) and 6-month (B) cytogenetic response (A = major; B = minor; C = other) to historical control patients receiving nonimatinib therapies (D).

randomized controlled trials may not be feasible because of ethical or other considerations.

This analysis provides evidence for a survival advantage with imatinib *versus* other treatments, by comparing the maturing results from the single-arm trials with imatinib in chronic-phase CML post-IFN failure to historical control populations. The first analysis compared the imatinib-treated study group to a historical control group of patients with chronic-phase CML post-IFN failure who received different treatment approaches (these would be considered acceptable “standards of care” because no standard of care existed). The analysis demonstrated a survival advantage with imatinib *versus* nonimatinib regimens (hazard ratio, 0.17;  $P < 0.0001$ ) by multivariate analysis, after accounting for important pretreatment prognostic factors. The second analysis compared only patients with 100% Ph-positive disease treated with imatinib for late chronic-phase CML to patients treated with IFN for late chronic-phase CML. Whereas this analysis compared two study groups with one major different factor (IFN failures *versus* IFN-naïve patients) it may be justified for three reasons. First, it compared imatinib therapy to an accepted standard of care, IFN. Second, patients in late chronic-phase CML have a similar prognosis whether they had or did not have exposure to IFN therapy (21, 22). Third, even if the latter argument was disputed, the IFN-failure patients would be expected logically to have a worse outcome than the IFN-naïve patient. Thus, the multivariate analysis, demonstrating the survival advantage with imatinib over IFN in late chronic-phase CML (hazard ratio, 0.20;  $P < 0.001$ ), after accounting for pretreatment important prognostic factors, provided a second line of evidence for the superiority of imatinib over other therapies in relation to survival in CML. As expected, in both analyses, imatinib was associated with significantly higher com-

Table 7 Landmark analysis of survival with imatinib versus other therapies by the degree of cytogenetic response at 3 and 6 months

|                                  | Estimated 3-year survival from start of therapy (%) |                   |       |                   |        |
|----------------------------------|-----------------------------------------------------|-------------------|-------|-------------------|--------|
|                                  | Imatinib                                            |                   | Other |                   | P      |
|                                  | No.                                                 | 3-yr survival (%) | No.   | 3-yr survival (%) |        |
| Cytogenetic response at 3 months |                                                     |                   |       |                   |        |
| Major                            | 115                                                 | 98                | 34    | 80                | 0.01   |
| Minor                            | 31                                                  | 92                | 10    | 60                | 0.04   |
| Other                            | 114                                                 | 84                | 104   | 54                | 0.0008 |
| Cytogenetic response at 6 months |                                                     |                   |       |                   |        |
| Major                            | 106                                                 | 97                | 33    | 82                | 0.07   |
| Minor                            | 27                                                  | 100               | 7     | 86                | 0.27   |
| Other                            | 84                                                  | 85                | 72    | 57                | 0.01   |

plete and major cytogenetic response rates, these being early surrogate endpoints for survival benefit with IFN therapy in several studies (27–30).

In a recent study by Marin *et al.* (31), 143 patients treated with imatinib for chronic-phase CML post-IFN failure were compared with 246 historical controls who received conventional treatment. They reported that patients on imatinib showed an overall survival advantage (relative risk, 0.54). However, whereas patients who achieved some cytogenetic response after 6 months had better survival than controls (relative risk, 0.13), those who did not have a cytogenetic response had a significantly worse survival (relative risk, 1.69). Our results contrast with their findings: survival with imatinib was significantly superior to historical controls whether patients did or did not achieve a cytogenetic response at 3 or 6 months (Fig. 4; Table 7). Moreover, within each cytogenetic response category, survival with imatinib was superior to other therapies, indicating a better quality/durability of cytogenetic response and better disease control with imatinib (Table 7).

In summary, this analysis of imatinib therapy in chronic-phase CML provided support for its beneficial effect on survival compared with nonimatinib therapies post-IFN failure, and compared with IFN therapy in late chronic-phase CML. The survival benefit with imatinib over historical controls is noted even in patients who do not achieve a cytogenetic response. Within each cytogenetic response category achieved with imatinib or other therapies, survival was superior with imatinib compared with other therapies.

## REFERENCES

1. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. *Nat. Med.*, 2: 561–566, 1996.
2. Beran, M., Cao, X., Estroz, Z., Jeha, S., Jin, G., O'Brien, S., Talpaz, M., Arlinghaus, R. B., Lydon, N. B., and Kantarjian, H. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). *Clin. Cancer Res.*, 4: 1661–1672, 1998.
3. Druker, B. J., Talpaz, M., Resta, D. J., Peny, B., Buchdunger, E., Ford, J., *et al.* Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N. Engl. J. Med.*, 344: 1031–1037, 2001.
4. Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., and Talpaz, M. Activity of a specific

inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *N. Engl. J. Med.*, 344: 1038–1042, 2001.

5. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M., and Druker, B. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. *N. Engl. J. Med.*, 346: 645–652, 2002.
6. Kantarjian, H., Talpaz, M., O'Brien, S., Smith, T. L., Giles, F. J., Faderl, S., Thomas, D. A., Garcia-Manero, G., Issa, J. P., Andreeff, M., Kornblau, S. M., Koller, C., Beran, M., Kearing, M., Rios, M. B., Shan, J., Resta, D., Capdeville, R., Hayes, K., Albitar, M., Freireich, E. J., and Cortes, J. E. Imatinib mesylate for Philadelphia chromosome-positive chronic-phase myeloid leukemia after failure of interferon- $\alpha$ : follow-up results. *Clin. Cancer Res.*, 8: 2177–2187, 2002.
7. Talpaz, M., Silver, R. T., Druker, B. J., Goldman, J. M., Gambacorti-Passerini, C., Guilhot, F., Schiffer, C. A., Fischer, T., Deininger, M. W., Lennard, A. L., Hochhaus, A., Ottmann, O. G., Gratwohl, A., Baccarani, M., Stone, R., Tura, S., Mahon, F. X., Fernandes-Reese, S., Gathmann, I., Capdeville, R., Kantarjian, H. M., and Sawyers, C. L. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. *Blood*, 99: 1928–1937, 2002.
8. Kantarjian, H., O'Brien, S., Cortes, J., Smith, T. L., Rios, M. B., Shan, J., Yang, Y., Giles, F. J., Thomas, D. A., Faderl, S., Garcia-Manero, G., Jeha, S., Wierda, W., Issa, J. P., Kornblau, S. M., Keating, M., Resta, D., Capdeville, R., and Talpaz, M. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. *Clin. Cancer Res.*, 8: 2167–2176, 2002.
9. Sawyers, C. L., Hochhaus, A., Feldman, E., Goldman, J. M., Miller, C. B., Ottman, O. G., Schiffer, C. A., Talpaz, M., Guilhot, F., Deininger, M. W., Fischer, T., O'Brien, S. G., Stone, R. M., Gambacorti-Passerini, C. B., Russell, N. H., Reiffers, J. J., Shea, T. C., Chapuis, B., Courtre, S., Tura, S., Morra, E., Larson, R. A., Saven, A., Peschel, C., Gratwohl, A., Mandelli, F., Ben Am, M., Gathmann, I., Capdeville, R., Paquette, R. L., and Druker, B. J. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. *Blood*, 99: 3530–3539, 2002.
10. Kantarjian, H. M., Cortes, J., O'Brien, S., Giles, F. J., Albitar, M., Rios, M. B., Shan, J., Faderl, S., Garcia-Manero, G., Thomas, D. A., Resta, D., and Talpaz, M. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. *Blood*, 99: 3547–3553, 2002.
11. O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., Lechner, K., Nielsen, J. L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd, J., Simonsson, B., Gratwohl, A., Goldman, J. M., Kantarjian, H., Taylor, K., Verhoef, G., Bolton, A. E., Capdeville, R., and Druker, B. J., for the IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *N. Engl. J. Med.*, 348: 994–1004, 2003.

12. Kantarjian, H., Cortes, J., O'Brien, S., Giles, F., Garcia-Manero, G., Faderl, S., Thomas, D., Jeha, S., Rios, M. B., Letvak, L., Bochinski, K., Arlinghaus, R., and Talpaz, M. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. *Blood*, *101*: 97–100, 2003.
13. Benson, B. A., and Hartz, A. A comparison of observation studies and randomized, controlled trials. *N. Engl. J. Med.*, *342*: 1878–1886, 2000.
14. Concato, J., Shah, N., and Horwitz, R. I. Randomized controlled trials, observational studies, and the hierarchy of research designs. *N. Engl. J. Med.*, *342*: 1887–1892, 2000.
15. Kantarjian, H. M., O'Brien, S., Smith, T. L., Rios, M. B., Cortes, J., Beran, M., Koller, C., Giles, F. J., Andreeff, M., Kornblau, S., Giralt, S., Keating, M. J., and Talpaz, M. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon  $\alpha$  and low-dose cytarabine. *J. Clin. Oncol.*, *17*: 284–292, 1999.
16. Talpaz, M., Kantarjian, H., Kurzrock, R., Trujillo, J. M., and Gutterman, J. U. Interferon  $\alpha$  produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. *Ann. Intern. Med.*, *114*: 532–538, 1991.
17. Kantarjian, H., Smith, T. L., O'Brien, S., Beran, M., Pierce, S., and Talpaz, M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon- $\alpha$  therapy. The Leukemia Service. *Ann. Intern. Med.*, *122*: 254–261, 1995.
18. Cox, D. R. Regression models and life tables (with discussion). *J. R. Statist. Soc.*, *34*: 187–220, 1972.
19. Hasford, J., Pffirmann, M., Hehlmann, R., Allan, N. C., Baccarani, M., Kluin-Nelemans, J. C., Alimena, G., Steegmann, J. L., and Ansari, H. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. *J. Natl. Cancer Inst.*, *90*: 850–858, 1998.
20. Sokal, J., Cox, E., Baccarani, M., Tura, S., Gomez, G. A., Robertson, J., Tso, C. Y., Braun, T. J., Clarkson, B. D., Cervantes, F., and the Italian Cooperative CML Study Group. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. *Blood*, *63*: 789–799, 1984.
21. Rodriguez, J., Cortes, J., Smith, T., O'Brien, S., Rios, M. B., Talpaz, M., and Kantarjian, H. Determinants of prognosis in late chronic phase myelogenous leukemia. *J. Clin. Oncol.*, *16*: 3782–3787, 1998.
22. Sacchi, S., Kantarjian, H., O'Brien, S., Beran, M., Koller, C., Pierce, S., Kornblau, S., Estey, E., Keating, M. J., and Talpaz, M. Long-term follow-up results of  $\alpha$ -interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia. *Leukemia (Baltimore)*, *11*: 1610–1616, 1997.
23. Chalmers, T. C., Celano, P., Sacks, H. S., and Smith, H., Jr. Bias treatment assignment in controlled clinical trials. *N. Engl. J. Med.* *309*: 1358–1361, 1983.
24. Sacks, H., Chalmers, T. C., and Smith, H., Jr. Randomized versus historical controls for clinical trials. *Am. J. Med.*, *72*: 233–240, 1982.
25. Colditz, G. A., Miller, J. N., and Mosteller, F. How study design affects outcomes in comparisons of therapy. I. *Med. Stat. Med.*, *8*: 441–454, 1989.
26. Miller, J. N., Colditz, G. A., and Mosteller, F. How study design affects outcomes in comparisons of therapy II. *Surg. Stat. Med.*, *8*: 455–466, 1989.
27. Mahon, F. X., Delbrel, X., Cony-Makhoul, P., Faberes, C., Boiron, J. M., Barthe, C., Bilhou-Nabera, C., Pigneux, A., Marit, G., and Reiffers, J. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon- $\alpha$ . *J. Clin. Oncol.*, *20*: 214–220, 2002.
28. Bonifazi, F., de Vivo, A., Rosti, G., Guilhot, F., Guilhot, J., Trabacchi, E., Hehlmann, R., Hochhaus, A., Shepherd, P. C., Steegmann, J. L., Kluin-Nelemans, H. C., Thaler, J., Simonsson, B., Louwagie, A., Reiffers, J., Mahon, F. X., Montefusco, E., Alimena, G., Hasford, J., Richards, S., Saglio, G., Testoni, N., Martinelli, G., Tura, S., and Baccarani, M. Chronic myeloid leukemia and interferon- $\alpha$ : a study of complete cytogenetic responders. *Blood*, *98*: 3074–3081, 2001.
29. Giles, F. J., Kantarjian, H., O'Brien, S., Rios, M. B., Cortes, J., Beran, M., Koller, C., Keating, M., and Talpaz, M. Results of therapy with interferon  $\alpha$  and cyclic combination chemotherapy in patients with Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. *Leuk. Lymphoma*, *41*: 309–319, 2001.
30. Kantarjian, H., O'Brien, S., Cortes, J., Shan, J., Giles, F. J., Rios, M. B., Faderl, S. H., Wierda, W. G., Ferrajoli, A., Verstovsek, S., Keating, M. J., Freireich, E. J., and Talpaz, M. Complete cytogenetic and molecular responses to interferon- $\alpha$ -based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. *Cancer (Phila.)*, *97*: 1033–1041, 2003.
31. Marin, D., Marktel, S., Szydlo, R., Klein, J. P., Bua, M., Foot, N., Olavarria, E., Shepherd, P., Kanfer, E., Goldman, J. M., and Apperley, J. Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. *Lancet*, *362*: 617–619, 2003.



# Clinical Cancer Research

## Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN- $\alpha$ Failure and in Late CML-CP, Comparison with Historical Controls

Hagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.

*Clin Cancer Res* 2004;10:68-75.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/10/1/68>

**Cited articles** This article cites 31 articles, 12 of which you can access for free at:  
<http://clincancerres.aacrjournals.org/content/10/1/68.full#ref-list-1>

**Citing articles** This article has been cited by 19 HighWire-hosted articles. Access the articles at:  
<http://clincancerres.aacrjournals.org/content/10/1/68.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://clincancerres.aacrjournals.org/content/10/1/68>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.